AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03151811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: Oral capsules
Study NCT03151811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral tablets
Study NCT03151811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Oral tablets
Study NCT01888679 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Head movement
Description: Head movement in extension, flexion, right and left rotation
Study NCT04023851 — intervention group
Intervention type: DEVICE
Intervention: Mobile application Brain4U
Description: Brain4U application provides participants to record seizures, medications, side effects, and combined psychiatric problems. It also reminds participants when to take antiepileptic drugs.
Study NCT00840450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gleevec/Paclitaxel
Description: One treatment cycle:~Gleevec: 300 mg twice a day orally for 4 consecutive days, then off for 3 days, every 7 days for 28 days.~Paclitaxel: 80 mg/m\^2/week intravenously, 3 weeks on, one week off, every 28 days.~After 3 treatment cycles, decision made to continue or not with the combination based on tolerance and lack of progression.
Study NCT03841669 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Group
Description: Guidelines for exercise programming (ACSM, 2018) will be followed including a warm up and cool down, progressive and gradual increments in duration, and instruction regarding avoidance of physical activity related injury. The exercise group will receive moderate to vigorous intensity aerobic exercise targeting 150 minutes per week for 12 months. The group will target dividing these minutes into 3 exercise sessions a week. The prescribed intensity will be based on their maximal fitness testing heart rate and then calculated per a research grade method. They will maintain a minimum heart rate from their specific calculation that will be monitored by Polar Heart Rate straps.
Study NCT03841669 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity & Health Information Group
Description: This group will not partake in the aerobic fitness sessions but will be asked to wear a daily monitoring device every 6 weeks. They will also complete all baseline, 6-month (optional), and 12-month visits.
Study NCT02495168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic Budesonide/Formoterol Fumarate Dihydrate
Description: Oral inhalation, generic formulation of the brand-name product.
Study NCT02495168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort® (Budesonide/Formoterol Fumarate Dihydrate)
Description: Oral inhalation, brand-name product.
Study NCT02495168 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral inhalation, no active ingredient.
Study NCT03254836 — intervention group
Intervention type: OTHER
Intervention: Standard of care
Description: Elective radical surgery for adenocarcinoma.
Study NCT02442518 — intervention group
Intervention type: PROCEDURE
Intervention: antenatal ultrasound
Description: Transabdominal and Transvaginal ultrasound examinations were performed in the third trimester (with some fluid in the bladder so that the uterine bladder interface could be evaluated well).
Study NCT04293120 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training with weighted ball
Description: Participants will stop or catch a weighted ball
Study NCT01603056 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pangramin SLIT HDM mix.
Description: Up-dosing phase (vial 0 to vial 4) + maintenance phase (3 times per week), for 12 months.
Study NCT01603056 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Up-dosing phase (vial 0 to vial 4) + maintenance phase (3 times per week), for 12 months.
Study NCT01484847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00299804
Description: Tablet, single dose of 45 mg via gastrojejunostomy tube (G-Tube) on an empty stomach
Study NCT02853604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADXS11-001
Study NCT02853604 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02688205 — intervention group
Intervention type: OTHER
Intervention: Cyriax's functional examination
Description: included active range of motion, passive range of motion, resisted test and accessory test for shoulder pain evaluation
Study NCT02688205 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound examination
Description: to evaluate rotator cuff, acromio-clavicular joint, and subdeltoid-subacromial bursa
Study NCT01482000 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary daoyin therapy of China
Description: The intervention group will perform a 3 months pulmonary daoyin of China therapy program which consists of training and patient education. They will be evaluated with some tests for the study.
Study NCT03209986 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cell
Description: mesenchymal stem cell infusion produced by Cell products of National Engineering Research Center(short for CPNERC), Tianjin, China
Study NCT02448797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: 125 mg three times daily (375 mg per day) orally for two years.
Study NCT02448797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Vinorelbine 25 mg/m\^2, intravenously guttae, day 1 and day 8, 21 days/cycle, 4 cycles, cisplatin 75 mg/m\^2, intravenously guttae, day 1, 21 days/cycle, 4 cycles. For adenocarcinoma: pemetrexed (500 mg/m\^2, day 1)/cisplatin (75 mg/m\^2, day 1) for 4 cycles.
Study NCT04469257 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sunbathing
Description: the individuals were exposed directly to sun in the nursing home garden on open and sunny days without sunscreen for five days a week for a month with an average of 21.0 ± 5.0 min (min 15 min - max 30 min). About 30-35% of their bodies (hand, face, neck, forearm open up to elbows and legs open up to the knee caps) were open.
Study NCT03577522 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Avenir cementless hip stem
Description: Avenir cementless hip stem vs Corail HA-coated hip stem
Study NCT03577522 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Corail HA-coated hip stem
Description: Avenir cementless hip stem vs Corail HA-coated hip stem
Study NCT01997138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg in 2 ml saline IA
Study NCT01997138 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anakinra 100 mg in 2 ml saline IA
Study NCT01482000 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: The control group will get the usual care with some additional tests for the study.
Study NCT03047694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tablet therapy
Description: stimulation of the lexico semantic system on a tactile tablet therapy for 3 months
Study NCT03047694 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: speech therapy
Study NCT01129817 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Functional Therapy
Description: A novel multidimensional classification system has been developed incorporating the biopsychosocial model, which subgroups patients based on their presentation with matched interventions directed at the maladaptive cognitive, physical and lifestyle behaviours associated with the disorder. The intervention is called 'cognitive functional therapy' as it directly challenges these behaviours in a functionally specific and graduated manner.
Study NCT01129817 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy and exercise
Description: Patients in this group was treated with joint mobilization or manipulation techniques applied to the spine or pelvis primarily and was designed to be consistent with best current manual therapy practice in Norway. The particular dose and techniques were at the discretion of the treating therapist, based on each participant's objective and physical examination findings. In addition most of the patients in this group was given exercises or a home exercise program.
Study NCT03434275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N1539
Description: Once Daily
Study NCT03434275 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once Daily
Study NCT01701856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b
Description: 250 mcg, s.c., each other day for 12 months
Study NCT01081834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks (Main Study) or 26 weeks (High Glycemic Substudy)
Study NCT01081834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One matching placebo capsule orally once daily for 26 weeks (Main Study)
Study NCT01081834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: One 100 mg over-encapsulated tablet orally once daily beginning at Week 26 until Week 52 (Main Study)
Study NCT01161407 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 1500 mg/d elemental calcium as calcium carbonate
Description: 500 mg elemental calcium as calcium carbonate given 3 times per day with meals for a total of 1500 mg/d elemental calcium. Given for 21 days in conjunction with a controlled diet.
Study NCT01161407 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for calcium carbonate in same capsule form. Given 3 times per day with meals for 21 days in conjunction with a controlled diet.
Study NCT02377050 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Higher Volume Feeding Goal
Description: feeding volume goal of 180-200 ml/kg/day
Study NCT03256279 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: .014 NiTi heat-activated archwire
Description: .014 NiTi heat-activated archwire In the lower arch during the first three months of the orthodonci treatment
Study NCT03256279 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: .014 NiTi Superelastic archwire
Description: .014 NiTi superelastic archwireIn the lower arch during the first three months of the orthodonci treatment
Study NCT03294902 — intervention group
Intervention type: DEVICE
Intervention: Pedra Tissue Perfusion Monitor
Description: This study is a prospective single-centre, device observational study designed to enroll up to 60 evaluable subjects at 1 investigational site in the United Kingdom. Eligible subjects, who meet the requirements for one of the 3 distinct subject groups: (1) Critical Limb Ischaemia group, (2) Peripheral artery disease with superficial femoral arterial (SFA) or popliteal artery disease and (3) PAD-free group. Subjects who meet study eligibility criteria will be enrolled consecutively until the total number of subjects is enrolled per each group as outlined in the protocol. All subjects at the investigational site will be enrolled in the presence of a member of the Sponsor or selected designee in order to assist with the device operation and to verify that all protocol assessments are completed appropriately at baseline.
Study NCT03645369 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ShotBlocker
Description: ShotBlocker is a drug-free tool with no side effects and does not require preparation. It is a flexible, plastic, C-shaped device with a number of short (2 mm) blunt contact points on its back.
Study NCT01274676 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: carotid stenting with MOMA
Description: The MOMA system is an endovascular catheter for proximal protection during carotid stenting. The system allows a concomitant balloon occlusion of both external and common carotid arteries leading to blood flow reversal within the internal carotid artery.
Study NCT01274676 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid stenting with filter wire EZ
Description: The filter wire EZ a distal protection system that is placed in he distal internal carotid artery before carotid stenting. The filter should entrap almost all the debries that are generated during endovascular procedure. At the end of the procedure the filter is retrieved throught a dedicated retrieval catheter.
Study NCT03645369 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ice pack
Description: Ice pack containing gel
Study NCT02487602 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gelesis100
Description: Gelesis100 capsules
Study NCT02487602 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gelesis100
Description: Gelesis100 capsules
Study NCT02487602 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Sucrose (sugar) capsules
Study NCT02487602 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sucrose (sugar) capsules
Study NCT02487602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sucrose (sugar) capsules
Study NCT01780818 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Air Insufflation method.
Description: Colonoscopy will be performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
Study NCT01780818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Immersion method.
Description: Air will not be insufflated until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if >3) if the lumen cannot be seen. Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal.
Study NCT01780818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Exchange method.
Description: Air will not be insufflated until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Suction of water will also be applied when colonoscope insertion proceeds smoothly. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned.
Study NCT02732119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: supplied in 50 mg, 200 mg capsules/tablets taken orally and dosed daily for 28 day cycle
Study NCT02732119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: supplied in 2.5 mg tablets taken orally, daily for 28 day cycle
Study NCT01894074 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lifestyle counseling: standard dietary education and counseling with a goal of reducing to 1500-1800 kcal/day
Study NCT03420196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised exercise program
Description: It will consist in a supervised exercise program, including the following exercises:~* Diaphragmatic breathing.~* Transverse abdomLateral leg raise for gluteus mediuminis muscle activation.~* Pelvic swing.~* Gluteus bridge.~* Spinal mobility.~* Spinal extensor muscles strengthening~* Frontal plank~* Side plank.~* Lateral leg raise for gluteus medium
Study NCT03420196 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non supervised exercise program
Description: It will consist in a non supervised exercise program, including the following exercises:~* Diaphragmatic breathing.~* Transverse abdomLateral leg raise for gluteus mediuminis muscle activation.~* Pelvic swing.~* Gluteus bridge.~* Spinal mobility.~* Spinal extensor muscles strengthening~* Frontal plank~* Side plank.~* Lateral leg raise for gluteus medium
Study NCT03479411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole Powder
Description: Itraconazole administered as a dry powder for inhalation (PUR1900)
Study NCT03479411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole Powder
Description: Itraconazole administered as a dry powder for inhalation (PUR1900)
Study NCT03479411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole 200 mg
Description: Sporanox® Oral Solution
Study NCT02084420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole
Description: 10mg 2 BID( 2 times / day), before breakfast and dinner
Study NCT02084420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: 40mg, BID(2 times / day), before breakfast and dinner
Study NCT01816672 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AutoloGel
Description: Treatment with Autologel and standard of care twice a week for the first two weeks and once a week thereafter
Study NCT01816672 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual and Customary Care
Description: Standard of care treatment twice weekly for 2 weeks then weekly
Study NCT05369936 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Description: Lavender will be inhaled through three phases
Study NCT05369936 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vapors of the distal water will be inhaled through three phases
Study NCT01854385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Description: This is a single-arm, unblinded study of treatment for post-traumatic headache with the open label medication sumatriptan and is being undertaken to test necessary study instruments and procedures, establish feasibility and determine side effects in a population with complicated mild, moderate and severe TBI.
Study NCT04570072 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Patients receive the formula probiotic for consecutive 8 weeks ( one sachet per day ).
Study NCT04570072 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receive the placebo identical to probiotic for consecutive 8 weeks ( one sachet per day ).
Study NCT03706521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM04690
Description: Healthcare professional-administered intra-articular injection performed once on Day 1 of the study.
Study NCT03980613 — intervention group
Intervention type: OTHER
Intervention: Triage
Description: Emergency telephone calls from cases and controls are replayed and analyzed for symptom descriptions indicating spontaneous subarachnoid haemorrhage.
Study NCT03537716 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with High Intensity Focused ElectroMagnetic system
Description: The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the abdomen area. Visible contractions will be induced by the device.
Study NCT02297698 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeuVax vaccine
Description: At the time of vaccine administration, a frozen solution of E75 acetate (1.5 mg/mL) is thawed and 1000mcg E75 peptide mixed thoroughly with 250mcg GM-CSF. This constitutes the NeuVax vaccine. Patients randomized to this arm will receive vaccinations of nelipepimut-S/GM-CSF administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of trastuzumab infusion. The first vaccination will be given with the third dose of maintenance trastuzumab administered as monotherapy optimally, but may be given with later maintenance doses of trastuzumab, provided there are at least six remaining doses of trastuzumab to overlap with the primary vaccine series.
Study NCT02297698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Herceptin will be administered to patients every three weeks as monotherapy for one year, to be given upon completion of standard of care chemotherapy/radiotherapy. The first trastuzumab infusion will be given no sooner than three weeks and no later than 12 weeks after completion of chemotherapy/radiotherapy. Trastuzumab will be dosed at the recommended initial loading dose of 8 mg/kg and at recommended maintenance doses of 6 mg/kg q3wk.
Study NCT02297698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Herceptin will be administered to patients every three weeks as monotherapy for one year, to be given upon completion of standard of care chemotherapy/radiotherapy. The first trastuzumab infusion will be given no sooner than three weeks and no later than 12 weeks after completion of chemotherapy/radiotherapy. Trastuzumab will be dosed at the recommended initial loading dose of 8 mg/kg and at recommended maintenance doses of 6 mg/kg q3wk.
Study NCT02297698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GM-CSF
Description: For patients randomized to the GM-CSF alone arm, they will receive inoculations of GM-CSF (250mcg) administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of trastuzumab infusion. The first injection will be given with the third dose of maintenance trastuzumab administered as monotherapy optimally, but may be given with later maintenance doses of trastuzumab, provided there are at least six remaining doses of trastuzumab to overlap with the primary vaccine series.